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Letter to the editor: A genetic-based algorithm for personalized resistance training 
Abstract 
In   a   recent   paper   entitled   “A   genetic-based   algorithm   for   personalized   resistance   training”,  
Jones et al. [1] presented an algorithm of 15 performance-associated gene polymorphisms that 
they propose can   determine   an   athlete’s   training   response   by   predicting   power   and   endurance  
potential. However, from the design of their studies and the data provided, there is no 
evidence to support these authors’ assertions. Progress towards such a significant 
development in the field of sport and exercise genomics will require a paradigm shift in line 
with recent recommendations for international collaborations such as the Athlome Project 
(see www.athlomeconsortium.org). Large-scale initiatives, involving numerous multi-centre 
and well-phenotyped exercise training and elite performance cohorts, will be necessary before 
attempting to derive and replicate training and/or performance algorithms. 
Comment 
In   a   recent   paper   entitled   “A   genetic-based algorithm for personalized resistance training”, 
Jones et al. [1] proposed an algorithm of 15 performance-associated gene polymorphisms that 
they assert can determine an athlete’s training response by predicting power and endurance 
potential. Two studies were conducted and involved athletes from several sports (e.g. 
swimming, ski/snowboard, squash, motorsport, and football players) undergoing an eight-
week high- or low-intensity resistance training intervention comprising of one or two training 
sessions per week; participants continued sport-specific training and competition during the 
intervention period. The DNAFit Peak Performance AlgorithmTM was used to calculate 
percentage power/endurance score ratio using the 15 gene polymorphisms. Briefly, this 
involved the summation of assigning a point from 0-4, depending on the putative effect of 
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each allele on power and/or endurance performance. Based on this derived power/endurance
score, subjects were assigned to either an endurance or power genotype training group
involving low-intensity or high-intensity resistance training, respectively. The only 
associations reported were between 5 of the 15 gene polymorphisms and training response as 
assessed by a countermovement jump (CMJ) and an aerobic-3 min cycle test (Aero3) 
determined before and after the intervention; albeit none of these associations reached 
statistical significance. The authors also reported an increase in CMJ and Aero3 performance 
when assessed within each of the two training groups. On the basis of these results, the
authors concluded that the DNAFit Peak Performance AlgorithmTM can be used for
personalised resistance-training prescription.
It is clear from the study design and the data provided by Jones et al. that there is no evidence 
to support these   authors’   assertions. The DNAFit Peak Performance AlgorithmTM used by 
these authors comprises 15 polymorphisms in 14 genes (ACE, ACTN3, ADRB2, AGT, 
BDKRB2, COL5A1, CRP, GABPB1, IL6, PPARA, PPARGC1A, TRHR, VDR and VEGFA); 
most of which have been associated, albeit tentatively with sports performance in the 
literature (see Table 1 and [2]). To our knowledge, there is no direct evidence linking CRP 
(rs1205) polymorphism to endurance performance (not included in Table 1); this specific 
polymorphism has recently been linked to a protective effect in the pathogenesis of 
cardiovascular heart disease in a meta-analysis [3]. The 15 gene polymorphisms have been 
“identified”   primarily using the candidate gene approach and applied to cohorts with small 
sample sizes [4, 5]. As presented in Table 1, there are positive and negative findings for some 
genetic markers but few of these polymorphisms have been replicated. Notably, for the TRHR 
gene variant, there is only one study supporting the link with lean body mass variation [6, 7] 
in 1000 US whites after several replication attempts in three different cohorts consisting of in 
total over 6000 white US and Chinese participants. The Vitamin D receptor BsmI (rs1544410) 
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polymorphism has also been associated with muscle strength in elderly population in three 
studies but results remain inconclusive [8]. In contrast, ACE I/D and ACTN3 R577X have 
been extensively studied and replicated to some degree in different populations [9], these two 
polymorphisms (together, separately, or part of an algorithm) do not predict training response
[2, 10, 11]. 
It is widely acknowledged that a single gene or a combination of a few genes (using genotype 
score) may explain a very low percentage of sports performance variation, for example, a 2-
3% of sprinting performance variability may be explained by ACTN3 genotype [11, 12]. 
Nevertheless, a recent meta-analysis of genome-wide association studies and their replications 
reported that common genetic variants could not discriminate elite endurance athletes from 
respective control populations (GENATHLETE, Japan, Australia, Poland, Russia, Spain, 
Kenya, and Ethiopia) [13]. Therefore, the research evidence to date to support the selection of 
any polymorphism is weak [11, 14, 15]. Timmons et al. and Bouchard et al. were the first to 
investigate training response using genome-wide exploration. Timmons et al. reported a 
discovery of 29 transcripts that predicted maximum oxygen uptake (V̇O2max) training 
response, and these transcripts contained 11 single-nucleotide polymorphisms (SNPs) 
explaining 23% of the variance in gains in V̇O2max [16]. Bouchard et al. used data from the 
HERITAGE study (Health, Risk factors, Training and Genetics) and identified a set of 21 
SNPs accounting for 49% of the variance in V̇O2max trainability [17]. However, none of the 
training-associated SNPs reported by Timmons et al. [16] were replicated by Bouchard et al. 
[17], nor were any of the “putative”   training-associated SNPs reported in either study used in 
the DNAFit Peak Performance AlgorithmTM. The study by Jones et al. also highlights a 
number of methodological problems typically associated with the sport and exercise genomics 
literature [18] such as small sample size, sports variation and low number of training sessions. 
For example, both experiments in the Jones et al. employed very small sample sizes of 28 and 
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39 participants, respectively. Although authors stated that the sample sizes used were
sufficient after power calculation, details of the power calculation were not provided and is 
most unlikely given the data presented and on the basis of other studies [19-21]. Progress
towards developing training and/or performance algorithms will require a paradigm shift in
line with recent recommendations for international collaborations [22] such as the Athlome
Project (see www.athlomeconsortium.org). Such large-scale initiatives, designed specifically 
to overcome many of the limitations of small single-site studies will be necessary before
attempting to derive and replicate training and performance algorithms. 
In conclusion, while it is widely acknowledged that a favourable genotype combined with 
suitable training will enhance trainability and sporting performance, to date few (i.e. ACTN3 
and ACE) polymorphisms have been associated with an acceptable level of replication with 
endurance or power athletic performance, and none of these associations are strong enough to 
predict elite sports performance or trainability [14, 23, 24]. Currently, there is lack of 
scientific evidence supporting the predictive values of genetic tests (direct-to-consumer) for 
prescription of exercise training programmes, or for that matter, talent identification. Further 
studies with replication are needed in order for genetic variants to be used in personalised 
training prescription. As stated by Webborn et al., research findings should not be 
misinterpreted for commercial purposes. Jones et al. [1] are premature in their attempt to 
demonstrate that a genetic test using DNAfit Peak AlgorithmTM can determine the training 
response by predicting power and endurance potential. There are important limitations in their 
study design and interpretation of their results. Their suggestion of using a somewhat 
ambiguous algorithm to prescribe individualised training is premature. While acknowledging 
the difficulties in translating research discoveries, it is the responsibility of researchers to be 
cautious and not to over-interpret their research findings as this can motivate unsubstantiated 
commercial exploitation. Sarzynski et al. recently developed a framework for translating 
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research discoveries that included useful information on sample size requirements and 
preferred technologies for discovery and replication phases of genetic research with particular 
reference to exercise genomics[25].
References 
1. Jones N KJ, Suraci B, Collins DJ, de Lorenzo D, Pickering C, Grimaldi KA. A
genetic-based algorithm for personalized resistance training. Biol Sport. 2016;33(2):117-26. 
2. Wang G, Padmanabhan S, Wolfarth B, Fuku N, Lucia A, Ahmetov, II, Cieszczyk P,
Collins M, Eynon N, Klissouras V, Williams A, Pitsiladis Y. Genomics of elite sporting 
performance: what little we know and necessary advances. Advances in genetics. 
2013;84:123-49. 
3. Hernández-Díaz   Y,   Tovilla-Zárate   CA,   Juárez-Rojop   I,   Baños-González   MA,   Torres-
Hernández   ME,   López-Narváez   ML,   Yañez-Rivera   TG,   González-Castro TB. The role of 
gene variants of the inflammatory markers CRP and TNF-α   in   cardiovascular   heart   disease:  
systematic review and meta-analysis. Int J Clin Exp Med. 2015;8(8):11958-84. 
4. Pitsiladis Y, Wang G, Wolfarth B, Scott R, Fuku N, Mikami E, He Z, Fiuza-Luces C,
Eynon N, Lucia A. Genomics of elite sporting performance: what little we know and 
necessary advances. British journal of sports medicine. 2013;47(9):550-5. 
5. Tanaka M, Wang G, Pitsiladis YP. Advancing sports and exercise genomics: moving
from hypothesis-driven single study approaches to large multi-omics collaborative science. 
Physiological genomics. 2016;48(3):173-4. 
6. Roth SM. Genetic aspects of skeletal muscle strength and mass with relevance to
sarcopenia. Bonekey Rep. 2012;1:58. 
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120

7. Liu XG, Tan LJ, Lei SF, Liu YJ, Shen H, Wang L, Yan H, Guo YF, Xiong DH, Chen 
XD, Pan F, Yang TL, Zhang YP, Guo Y, Tang NL, Zhu XZ, Deng HY, Levy S, Recker RR, 
Papasian CJ, Deng HW. Genome-wide association and replication studies identified TRHR as
an important gene for lean body mass. Am J Hum Genet. 2009;84(3):418-23. 
8. Garatachea   N,   Lucía   A.   Genes   and   the   ageing   muscle:   a   review   on   genetic   association
studies. Age (Dordr). 2013;35(1):207-33. 
9. Ma F, Yang Y, Li X, Zhou F, Gao C, Li M, Gao L. The association of sport
performance with ACE and ACTN3 genetic polymorphisms: a systematic review and meta-
analysis. PloS one. 2013;8(1):e54685. 
10. Guth LM, Roth SM. Genetic influence on athletic performance. Current opinion in
pediatrics. 2013;25(6):653-8. 
11. Webborn N, Williams A, McNamee M, Bouchard C, Pitsiladis Y, Ahmetov I, Ashley
E, Byrne N, Camporesi S, Collins M, Dijkstra P, Eynon N, Fuku N, Garton FC, Hoppe N, 
Holm S, Kaye J, Klissouras V, Lucia A, Maase K, Moran C, North KN, Pigozzi F, Wang G. 
Direct-to-consumer genetic testing for predicting sports performance and talent identification: 
Consensus statement. British journal of sports medicine. 2015;49(23):1486-91. 
12. Moran CN, Yang N, Bailey ME, Tsiokanos A, Jamurtas A, MacArthur DG, North K,
Pitsiladis YP, Wilson RH. Association analysis of the ACTN3 R577X polymorphism and 
complex quantitative body composition and performance phenotypes in adolescent Greeks. 
Eur J Hum Genet. 2007;15(1):88-93. 
13. Rankinen T, Fuku N, Wolfarth B, Wang G, Sarzynski MA, Alexeev DG, Ahmetov, II,
Boulay MR, Cieszczyk P, Eynon N, Filipenko ML, Garton FC, Generozov EV, Govorun VM, 
Houweling PJ, Kawahara T, Kostryukova ES, Kulemin NA, Larin AK, Maciejewska-
Karlowska A, Miyachi M, Muniesa CA, Murakami H, Ospanova EA, Padmanabhan S, 
Pavlenko AV, Pyankova ON, Santiago C, Sawczuk M, Scott RA, Uyba VV, Yvert T, Perusse 
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145

L, Ghosh S, Rauramaa R, North KN, Lucia A, Pitsiladis Y, Bouchard C. No Evidence of a 
Common DNA Variant Profile Specific to World Class Endurance Athletes. PloS one. 
2016;11(1):e0147330.
14. Camporesi S, McNamee MJ. Ethics, genetic testing, and athletic talent: children's best
interests, and the right to an open (athletic) future. Physiological genomics. 2016;48(3):191-5. 
15. Eynon N, Hanson ED, Lucia A, Houweling PJ, Garton F, North KN, Bishop DJ.
Genes for elite power and sprint performance: ACTN3 leads the way. Sports medicine. 
2013;43(9):803-17. 
16. Timmons JA, Knudsen S, Rankinen T, Koch LG, Sarzynski M, Jensen T, Keller P,
Scheele C, Vollaard NB, Nielsen S, Akerstrom T, MacDougald OA, Jansson E, Greenhaff PL, 
Tarnopolsky MA, van Loon LJ, Pedersen BK, Sundberg CJ, Wahlestedt C, Britton SL, 
Bouchard C. Using molecular classification to predict gains in maximal aerobic capacity 
following endurance exercise training in humans. Journal of applied physiology. 
2010;108(6):1487-96. 
17. Bouchard C, Sarzynski MA, Rice TK, Kraus WE, Church TS, Sung YJ, Rao DC,
Rankinen T. Genomic predictors of the maximal O(2) uptake response to standardized 
exercise training programs. Journal of applied physiology. 2011;110(5):1160-70. 
18. Pitsiladis Y, Wang G. Necessary advances in exercise genomics and likely pitfalls.
Journal of applied physiology. 2011;110(5):1150-1. 
19. Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for studying complex
genetic traits: practical considerations. Nature reviews Genetics. 2002;3(5):391-7. 
20. Long AD, Langley CH. The power of association studies to detect the contribution of 
candidate genetic loci to variation in complex traits. Genome research. 1999;9(8):720-31. 
21. Lalouel JM, Rohrwasser A. Power and replication in case-control studies. American
journal of hypertension. 2002;15(2 Pt 1):201-5. 
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170

22. Bouchard C. Exercise genomics-a paradigm shift is needed: a commentary. British 
journal of sports medicine. 2015;49(23):1492-6. 
23. Collins M, September AV, Posthumus M. Biological variation in musculoskeletal 
injuries: current knowledge, future research and practical implications. British journal of 
sports medicine. 2015;49(23):1497-503. 
24. Mattsson CM, Wheeler MT, Waggott D, Caleshu C, Ashley EA. Sports genetics
moving forward: lessons learned from medical research. Physiological genomics. 
2016;48(3):175-82. 
25. Sarzynski   MA,   Loos   RJ,   Lucia   A,   Pérusse L, Roth SM, Wolfarth B, Rankinen T,
Bouchard C. Advances in Exercise, Fitness, and Performance Genomics in 2015. Medicine 
and science in sports and exercise. 2016. 
26. Ahmetov II, Fedotovskaya ON. Current Progress in Sports Genomics. Adv Clin
Chem. 2015;70:247-314. 
171
172
173
174
175
176
177
178
179
180
181
182
183

Table 1. Gene variants for endurance and power/strength athlete status (Adapted from [26]). 
Gene Polymorphism 
Endurance 
related 
marker 
Power/ strength- 
related marker Endurance Power/Strength 
Number of 
studies with 
positive results 
Number of 
studies with 
negative or 
controversial 
results 
Number of 
studies with 
positive results 
Number of 
studies with 
negative or 
controversial 
results 
ACE Alu I/D (rs4646994) I D 16 12 7 7 
ACTN3 R577X (rs1815739 C/T) 577X Arg577 4 14 12 5 
ADRB2 Gly16Arg (rs1042713 G/A) 16Arg Gly16 2 1 1 - 
Gln27Glu (rs1042714 C/G) - 27Glu - - 1 - 
AGT Met235Thr (rs699 T/C) - 235Thr - - 2 - 
BDKRB2 rs1799722 C/T rs1799722 T - 1 - - - 
COL5A1 rs12722 C/T (BstUI) rs12722 T - 2 - - - 
GABPB1 
(NRF2) rs7181866 A/G rs7181866 G - 2 1 - - 
IL6 -174 C/G (rs1800795 C/G) - rs1800795 G - - 2 1 
PPARA rs4253778 G/C rs4253778 G rs4253778 C 5 - 2 1 
PPARGC1A Gly482Ser (rs8192678 G/A) Gly482 - 4 3 - - 
VEGFA rs2010963 G/C rs2010963 C - 1 - - - 
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